Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Hum Genet ; 109(8): 1472-1483, 2022 08 04.
Artigo em Inglês | MEDLINE | ID: mdl-35931051

RESUMO

Dyskeratosis congenita (DC) is an inherited bone-marrow-failure disorder characterized by a triad of mucocutaneous features that include abnormal skin pigmentation, nail dystrophy, and oral leucoplakia. Despite the identification of several genetic variants that cause DC, a significant proportion of probands remain without a molecular diagnosis. In a cohort of eight independent DC-affected families, we have identified a remarkable series of heterozygous germline variants in the gene encoding thymidylate synthase (TYMS). Although the inheritance appeared to be autosomal recessive, one parent in each family had a wild-type TYMS coding sequence. Targeted genomic sequencing identified a specific haplotype and rare variants in the naturally occurring TYMS antisense regulator ENOSF1 (enolase super family 1) inherited from the other parent. Lymphoblastoid cells from affected probands have severe TYMS deficiency, altered cellular deoxyribonucleotide triphosphate pools, and hypersensitivity to the TYMS-specific inhibitor 5-fluorouracil. These defects in the nucleotide metabolism pathway resulted in genotoxic stress, defective transcription, and abnormal telomere maintenance. Gene-rescue studies in cells from affected probands revealed that post-transcriptional epistatic silencing of TYMS is occurring via elevated ENOSF1. These cell and molecular abnormalities generated by the combination of germline digenic variants at the TYMS-ENOSF1 locus represent a unique pathogenetic pathway for DC causation in these affected individuals, whereas the parents who are carriers of either of these variants in a singular fashion remain unaffected.


Assuntos
Disceratose Congênita , Timidilato Sintase , Disceratose Congênita/genética , Células Germinativas , Heterozigoto , Humanos , Nucleotídeos , Timidilato Sintase/deficiência , Timidilato Sintase/genética
2.
Antimicrob Agents Chemother ; 59(12): 7265-72, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26369968

RESUMO

Trimethoprim-sulfamethoxazole (SXT) is a possible alternative for the treatment of community- and hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) due to the susceptibility of most MRSA strains to the drug. However, after long-term treatment with SXT, thymidine-dependent (TD) SXT-resistant small-colony variants (SCVs) emerge. In TD-SCVs, mutations of thymidylate synthase ([TS] thyA) occur. Until now, it has never been systematically investigated that SXT is triggering the induction and/or selection of TD-SCVs. In our study, we performed induction, reversion, and competition experiments in vitro and in vivo using a chronic mouse pneumonia model to determine the impact of SXT on the emergence of TD-SCVs. SCVs were characterized by light and transmission electron microscopy (TEM) and auxotrophism testing. Short-term exposure of S. aureus to SXT induced the TD-SCV phenotype in S. aureus SH1000, while selection of TD-SCVs with thyA mutations occurred after long-term exposure. In reversion experiments with clinical and laboratory TD-SCVs, all revertants carried compensating mutations at the initially identified mutation site. Competition experiments in vitro and in vivo revealed a survival and growth advantage of the ΔthyA mutant under low-thymidine availability and SXT exposure although this advantage was less profound in vivo. Our results show that SXT induces the TD-SCV phenotype after short-term exposure, while long-term exposure selects for thyA mutations, which provide an advantage for TD-SCVs under specified conditions. Thus, our results further an understanding of the dynamic processes occurring during SXT exposure with induction and selection of S. aureus TD-SCVs.


Assuntos
Antibacterianos/efeitos adversos , Proteínas de Bactérias/genética , Farmacorresistência Bacteriana/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Timidilato Sintase/genética , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Animais , Proteínas de Bactérias/metabolismo , Doença Crônica , Modelos Animais de Doenças , Farmacorresistência Bacteriana/genética , Expressão Gênica , Aptidão Genética/efeitos dos fármacos , Masculino , Staphylococcus aureus Resistente à Meticilina/enzimologia , Staphylococcus aureus Resistente à Meticilina/genética , Camundongos , Camundongos Endogâmicos C57BL , Mutação , Pneumonia Bacteriana/tratamento farmacológico , Seleção Genética/efeitos dos fármacos , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia , Timidina/metabolismo , Timidilato Sintase/deficiência
3.
Hum Vaccin Immunother ; 10(2): 333-7, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24196273

RESUMO

The concept of biological containment was developed as a strategy to prevent environmental dissemination of engineered live vaccine or drug delivery vehicles. A mutation in the gene encoding thymidylate synthase (thyA), a key enzyme in the pyrimidine biosynthetic pathway, has previously been shown to limit growth of L. lactis vectors under restrictive conditions. We hypothesized that further mutations in the pyrimidine biosynthetic pathway might enhance the stability and safety of live L. lactis vectors. We show that a double mutation in the genes encoding ThyA and CTP synthase (PyrG) in L. lactis confers double auxotrophy for both thymidine and cytidine. However, the combination of two mutations failed to enhance the biological containment phenotype of the engineered strain. In the absence of thymine/thymidine, the thyA mutant exhibited a strong bactericidal phenotype. However, creation of the double mutant caused the loss of this phenotype, though survival in the mouse GI tract was enhanced. The implications for biological containment of live L. lactis based delivery vectors are discussed.


Assuntos
Contenção de Riscos Biológicos , Portadores de Fármacos , Imunoterapia/métodos , Lactococcus lactis/enzimologia , Lactococcus lactis/crescimento & desenvolvimento , Vacinas/efeitos adversos , Vacinas/imunologia , Animais , Carbono-Nitrogênio Ligases/deficiência , Trato Gastrointestinal/microbiologia , Lactococcus lactis/genética , Camundongos , Timidilato Sintase/deficiência , Vacinas/administração & dosagem , Vacinas/genética
4.
Br J Cancer ; 103(3): 354-61, 2010 Jul 27.
Artigo em Inglês | MEDLINE | ID: mdl-20628382

RESUMO

BACKGROUND: Thymidylate synthase (TS), a key enzyme in the de novo synthesis of thymidine, is an important chemotherapeutic target for malignant tumours including lung cancer. Although inhibition of TS has an antiproliferative effect in cancer cells, the precise mechanism of this effect has remained unclear. METHODS: We examined the effects of TS inhibition with an RNA interference-based approach. The effect of TS depletion on the growth of lung cancer cells was examined using colorimetric assay and flow cytometry. RESULTS: Measurement of the enzymatic activity of TS in 30 human lung cancer cell lines revealed that such activity differs among tumour histotypes. Almost complete elimination of TS activity by RNA interference resulted in inhibition of cell proliferation in all tested cell lines, suggestive of a pivotal role for TS in cell proliferation independent of the original level of enzyme activity. The antiproliferative effect of TS depletion was accompanied by arrest of cells in S phase of the cell cycle and the induction of caspase-dependent apoptosis as well as by changes in the expression levels of cyclin E and c-Myc. Moreover, TS depletion induced downregulation of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP), and it seemed to activate the mitochondrial pathway of apoptosis. CONCLUSION: Our data provide insight into the biological relevance of TS as well as a basis for clinical development of TS-targeted therapy for lung cancer.


Assuntos
Neoplasias Pulmonares/tratamento farmacológico , Timidilato Sintase/genética , Adenocarcinoma/enzimologia , Adenocarcinoma/genética , Adenocarcinoma/patologia , Apoptose , Carcinoma de Células Grandes/enzimologia , Carcinoma de Células Grandes/genética , Carcinoma de Células Grandes/patologia , Carcinoma de Células Pequenas/enzimologia , Carcinoma de Células Pequenas/genética , Carcinoma de Células Pequenas/patologia , Carcinoma de Células Escamosas/enzimologia , Carcinoma de Células Escamosas/genética , Carcinoma de Células Escamosas/patologia , Caspase 3/metabolismo , Ciclo Celular/genética , Divisão Celular/genética , Linhagem Celular Tumoral , Ciclina E/genética , Citosol/metabolismo , Deleção de Genes , Regulação Neoplásica da Expressão Gênica , Humanos , Immunoblotting , Neoplasias Pulmonares/enzimologia , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patologia , Mitocôndrias/metabolismo , Proteínas Proto-Oncogênicas c-myc/genética , Interferência de RNA , Fase S/genética , Timidilato Sintase/antagonistas & inibidores , Timidilato Sintase/deficiência , Timidilato Sintase/metabolismo
5.
Cancer Res ; 69(3): 984-91, 2009 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-19155291

RESUMO

The major determinants of 5-flurouracil (5-FU) response would seem, based on accumulated literature, to be thymidylate synthase (TYMS, TS) expression levels, TS gene modifications, and TP53 status. We tested 5-FU sensitivity in yeast and human cancer cell models in which TS or TP53 alleles and expression were varied. Polymorphic TS tandem repeat status, TS expression levels reported, TS intragenic mutations, and TP53 status in outbred and experimental cancer cell lines did not predict 5-FU sensitivity or resistance. Novel observations included a dose-resistant persistence of unbound TS protein in many cancers and, upon 5-FU treatment of the colon cancer cell line, HCT116, evidence of allelic switching favoring transcripts of the mutant TS allele. The reported alleles having an intragenic mutation could not be causally associated with major degrees of 5-FU sensitivity. In yeast, TS protein was altered upon treatment with FdUMP, but 5-FU toxicity seemed to be largely RNA-based, being rescued by uridine rather than by thymidine. Cancer cell lines were also rescued from 5-FU toxicity with uridine rather than thymidine. Additionally, a TS (CDC21) knockout yeast strain, obviating any potential role for TS protein as a target, was hypersensitive to 5-FU. When denatured proteins from cancer cells treated with radiolabeled 5-FU were labeled, species with alternative molecular weights other than TS were visualized, providing further evidence for alternative 5-FU protein targets. These data emphasize that TS and TP53 status do not consistently explain the variance in responses of fluoropyrimidine-treated cancer cells, in part due to RNA-based toxicity.


Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Fluoruracila/farmacologia , Genes p53 , RNA Neoplásico/efeitos dos fármacos , Timidilato Sintase/biossíntese , Alelos , Sequência de Bases , Linhagem Celular Tumoral , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/enzimologia , Neoplasias Colorretais/genética , Células HCT116 , Humanos , Dados de Sequência Molecular , Mutação , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , RNA Neoplásico/genética , Timidina/farmacologia , Timidilato Sintase/deficiência , Timidilato Sintase/genética , Uridina/farmacologia , Leveduras/efeitos dos fármacos , Leveduras/enzimologia , Leveduras/genética
6.
Mol Cells ; 26(4): 344-9, 2008 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-18612238

RESUMO

5-Fluorouracil (5-FU), a pyrimidine antagonist, has a long history in cancer treatment. The targeted pyrimidine biosynthesis pathway includes dihydropyrimidine dehydrogenase (DPD), which converts 5-FU to an inactive metabolite, and thymidylate synthase (TS), which is a major target of 5-FU. Using Caenorhabditis elegans as a model system to study the functional and resistance mechanisms of anti-cancer drugs, we examined these two genes in order to determine the extent of molecular conservation between C. elegans and humans. Overexpression of the worm DPD and TS homologs (DPYD-1 and Y110A7A.4, respectively) suppressed germ cell death following 5-FU exposure. In addition, DPYD-1 depletion by RNAi resulted in 5-FU sensitivity, while treatment with Y110A7A.4 RNAi and 5-FU resulted in similar patterns of embryonic death. Thus, the pathway of 5-FU function appears to be highly conserved between C. elegans and humans at the molecular level.


Assuntos
Caenorhabditis elegans/efeitos dos fármacos , Caenorhabditis elegans/enzimologia , Di-Hidrouracila Desidrogenase (NADP)/metabolismo , Fluoruracila/farmacologia , Timidilato Sintase/metabolismo , Sequência de Aminoácidos , Animais , Caenorhabditis elegans/embriologia , Caenorhabditis elegans/genética , Deficiência da Di-Hidropirimidina Desidrogenase , Di-Hidrouracila Desidrogenase (NADP)/química , Di-Hidrouracila Desidrogenase (NADP)/genética , Desenvolvimento Embrionário/efeitos dos fármacos , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Humanos , Dados de Sequência Molecular , Fenótipo , Interferência de RNA/efeitos dos fármacos , Homologia de Sequência de Aminoácidos , Timidilato Sintase/química , Timidilato Sintase/deficiência , Timidilato Sintase/genética
7.
J Biol Chem ; 280(7): 5456-67, 2005 Feb 18.
Artigo em Inglês | MEDLINE | ID: mdl-15591067

RESUMO

Here we report on a Chlamydia trachomatis gene that complements the growth defect of a thymidylate synthase-deficient strain of Escherichia coli. The complementing gene encodes a 60.9-kDa protein that shows low level primary sequence homology to a new class of thymidylate-synthesizing enzymes, termed flavin-dependent thymidylate synthases (FDTS). Purified recombinant chlamydial FDTS (CTThyX) contains bound flavin. Results with site-directed mutants indicate that highly conserved arginine residues are required for flavin binding. Kinetic characterization indicates that CTThyX is active as a tetramer with NADPH, methylenetetrahydrofolate, and dUMP required as substrates, serving as source of reducing equivalents, methyl donor, and methyl acceptor, respectively. dTMP and H(4)folate are products of the reaction. Production of H(4)folate rather than H(2)folate, as in the classical thymidylate synthase reaction, eliminates the need for dihydrofolate reductase, explaining the trimethoprim-resistant phenotype displayed by thyA(-) E. coli-expressing CTThyX. In contrast to the extensively characterized thyA-encoded thymidylate synthases, which form a ternary complex with substrates dUMP and CH(2)H(4)folate and follow an ordered sequential mechanism, CTThyX follows a ping-pong kinetic mechanism involving a methyl enzyme intermediate. Mass spectrometry was used to localize the methyl group to a highly conserved arginine, and site-directed mutagenesis showed this arginine to be critical for thymidylate synthesizing activity. These differentiating characteristics clearly distinguish FDTS from ThyA, making this class of enzymes attractive targets for rational drug design.


Assuntos
Chlamydia trachomatis/enzimologia , Flavinas/metabolismo , Timidilato Sintase/metabolismo , Sequência de Aminoácidos , Catálise/efeitos dos fármacos , Chlamydia trachomatis/genética , Clonagem Molecular , Nucleotídeos de Desoxiuracil/metabolismo , Desenho de Fármacos , Escherichia coli/enzimologia , Escherichia coli/genética , Escherichia coli/crescimento & desenvolvimento , Flavinas/farmacologia , Ácido Fólico/metabolismo , Teste de Complementação Genética , Cinética , Dados de Sequência Molecular , NADP/metabolismo , Fases de Leitura Aberta/genética , Oxirredução , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz , Especificidade por Substrato , Timidina Monofosfato/metabolismo , Timidilato Sintase/química , Timidilato Sintase/deficiência , Timidilato Sintase/genética
9.
Nat Biotechnol ; 21(7): 785-9, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12808464

RESUMO

Genetically modified Lactococcus lactis secreting interleukin 10 provides a therapeutic approach for inflammatory bowel disease. However, the release of such genetically modified organisms through clinical use raises safety concerns. In an effort to address this problem, we replaced the thymidylate synthase gene thyA of L. lactis with a synthetic human IL10 gene. This thyA- hIL10+ L. lactis strain produced human IL-10 (hIL-10), and when deprived of thymidine or thymine, its viability dropped by several orders of magnitude, essentially preventing its accumulation in the environment. The biological containment system and the bacterium's capacity to secrete hIL-10 were validated in vivo in pigs. Our approach is a promising one for transgene containment because, in the unlikely event that the engineered L. lactis strain acquired an intact thyA gene from a donor such as L. lactis subsp. cremoris, the transgene would be eliminated from the genome.


Assuntos
Regulação Bacteriana da Expressão Gênica/fisiologia , Íleo/microbiologia , Interleucina-10/genética , Interleucina-10/metabolismo , Lactococcus lactis/genética , Lactococcus lactis/metabolismo , Engenharia de Proteínas/métodos , Timidilato Sintase/deficiência , Sequência de Aminoácidos , Animais , Divisão Celular , Sobrevivência Celular , Colite/microbiologia , Colite/terapia , Sistemas de Liberação de Medicamentos/métodos , Engenharia Genética/métodos , Humanos , Interleucina-10/uso terapêutico , Lactococcus lactis/citologia , Lactococcus lactis/crescimento & desenvolvimento , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Probióticos/uso terapêutico , Suínos , Timidilato Sintase/genética , Timidilato Sintase/metabolismo
10.
Appl Environ Microbiol ; 68(6): 3010-23, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12039762

RESUMO

The thyA gene, which encodes thymidylate synthase (TS), of Lactococcus lactis CHCC373 was sequenced, including the upstream and downstream regions. We then deleted part of thyA by gene replacement. The resulting strain, MBP71 deltathyA, was devoid of TS activity, and in media without thymidine, such as milk, there was no detectable dTTP pool in the cells. Hence, DNA replication was abolished, and acidification by MBP71 was completely unaffected by the presence of nine different phages tested at a multiplicity of infection (MOI) of 0.1. Nonreplicating MBP71 must be inoculated at a higher level than CHCC373 to achieve a certain pH within a specified time. For a pH of 5.2 to be reached in 6 h, the inoculation level of MBP71 must be 17-fold higher than for CHCC373. However, by adding a limiting amount of thymidine this could be lowered to just 5-fold the normal amount, while acidification was unaffected with MBP71 up to an MOI of 0.01. It was found that nonreplicating MBP71 produced largely the same products as CHCC373, though the acetaldehyde production of the former was higher.


Assuntos
Bacteriófagos/fisiologia , Replicação do DNA/fisiologia , Lactococcus lactis/virologia , Replicação Viral/fisiologia , Ensaio de Unidades Formadoras de Colônias , DNA Viral/fisiologia , Lactococcus lactis/genética , Lactococcus lactis/fisiologia , Mutação , Temperatura , Timidina/deficiência , Timidina/metabolismo , Timidilato Sintase/deficiência , Timidilato Sintase/genética , Timidilato Sintase/metabolismo , Nucleotídeos de Timina/análise
11.
J Biol Chem ; 275(14): 10023-9, 2000 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-10744679

RESUMO

Cell death due to thymine (dThd) deficiency, associated with the cytotoxic action of 5-fluorouracil in colon cancer, is regulated in thymidylate synthase-deficient (TS(-)) human colon carcinoma cells via the Fas (CD95, APO-1) death receptor. This was demonstrated by inhibiting the loss in clonogenicity of TS(-) cells by anti-FasL and in enhanced survival of TS(-) clones selected for resistance to Fas-mediated apoptosis, following dThd deprivation. During thymineless stress in TS(-) cells, Fas ligand (FasL) is expressed, and its promoter (hFasLPr) is activated. Transactivation of hFasLPr, dependent upon dThd deficiency, was inhibited following mutation of the binding sites for NF-kappaB or AP-1 and by preventing NF-kappaB or AP-1 activation, which inhibited expression of FasL and enhanced clonogenic survival in stable transformants expressing IkappaBalphaM or DN-MEKK, respectively. These results demonstrate the crucial roles for NF-kappaB and AP-1 in the regulation of FasL in Fas-mediated thymineless death of colon carcinoma cells.


Assuntos
Apoptose , Proteínas I-kappa B , Glicoproteínas de Membrana/metabolismo , NF-kappa B/metabolismo , Timina/metabolismo , Fator de Transcrição AP-1/metabolismo , Sobrevivência Celular , Células Clonais , Neoplasias do Colo , Proteínas de Ligação a DNA/metabolismo , Proteína Ligante Fas , Humanos , Glicoproteínas de Membrana/genética , Inibidor de NF-kappaB alfa , Regiões Promotoras Genéticas , Proteínas Recombinantes/metabolismo , Timidilato Sintase/deficiência , Ativação Transcricional , Transfecção , Células Tumorais Cultivadas
12.
Clin Exp Immunol ; 119(2): 299-304, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10632666

RESUMO

In this study we have compared the immune response of normal human cells cultured in vitro to two virulent strains of Leishmania major (CC1 and LV39), and to an avirulent vaccine strain (dhfr-ts-) made by targeted deletion of the essential gene DHFR-TS. We utilized an in vitro system in which naive T cells from normal human donors were primed with autologous Leishmania-infected macrophages. All three parasites infected macrophages and transformed into amastigotes within the cells. However, whereas LV39 and CC1 replicated in macrophages, dhfr-ts- did not. When peripheral blood lymphocytes (PBL) were stimulated with autologous macrophages infected with any of the three parasites, the lymphocytes produced a type-1-biased cytokine response. Finally, addition of IL-12 during the first stimulation period increased the production of interferon-gamma but decreased IL-5 secretion. On the other hand, anti-IL-12 resulted in the opposite effect.


Assuntos
Citocinas/biossíntese , Leishmania major/imunologia , Leishmania major/patogenicidade , Células Th1/imunologia , Animais , Células Cultivadas , Humanos , Interferon gama/biossíntese , Interleucina-12/fisiologia , Interleucina-5/biossíntese , Leishmania major/enzimologia , Leishmania major/genética , Tetra-Hidrofolato Desidrogenase/deficiência , Tetra-Hidrofolato Desidrogenase/genética , Células Th1/metabolismo , Células Th1/parasitologia , Células Th2/imunologia , Células Th2/metabolismo , Células Th2/parasitologia , Timidilato Sintase/deficiência , Timidilato Sintase/genética , Virulência
13.
Cancer Res ; 60(1): 92-100, 2000 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-10646859

RESUMO

Recent studies of fluoropyrimidine (FP)-mediated radiosensitization (RS) have focused on the molecular mechanisms underlying regulation of the cell cycle, particularly at the G1-S transition. Although thymidylate synthase (TS) inhibition by FP is necessary, we hypothesize that FP-RS is temporally dependent on progression of cells into S-phase under conditions of altered deoxynucleotide triphosphate pools, particularly an increased dATP:dTTP ratio, which subsequently results in enhanced DNA fragmentation and cell death. To better understand the mechanism of FP-RS, we characterized the cellular and biochemical responses to ionizing radiation (IR) alone, using different synchronization techniques in two isogenic, TS-deficient mutant cell lines, JH-1 (TS-) and JH-2 (Thy4), derived previously from a human colon cancer cell line. After G0 synchronization by leucine deprivation, these clones differ under subsequent growth conditions and dThd withdrawal: JH-2 cells have an intact G1 arrest (>72 h) and delayed cell death (>96 h), whereas JH-1 cells progress rapidly into early S-phase and undergo acute cell death (<24 h). No difference in the late S-phase and G2-M cell populations were noted between these growth-stimulated, G0-synchronized TS-deficient cell lines with dThd withdrawal. Biochemically, the intracellular ratio of dATP:dTTP increased substantially in JH-1 cells as cells progressed into early S-phase compared with JH-2 cells, which remained in G1 phase. Synchronized JH-1 cells showed significantly decreased clonogenic survival and an increase in DNA fragmentation after IR when compared with JH-2 cells. RS was demonstrated by an increase in alpha and decrease in beta, using linear quadratic analyses. An alternative synchronization technique used mimosine to induce a block in late G1, close to G1-S border. Both JH-1 and JH-2 cells, synchronized in late G1 and following growth stimulation, now progressed into S-phase identically (<24 h), with similarly increased dATP:dTTP ratios under dThd withdrawal conditions. These late G1-synchronized JH-1 and JH-2 cells also showed a comparable reduction in clonogenic survival and similar patterns of increased DNA fragmentation following IR. We suggest, based on the cellular and biochemical differences in response to IR between G0- and late G1-synchronized cells, that S-phase progression through the G1 restriction point under an altered (increased) dATP:dTTP ratio is a major determinant of FP-RS.


Assuntos
Desoxirribonucleosídeos/metabolismo , Fase G1/efeitos da radiação , Proteínas de Neoplasias/deficiência , Fase de Repouso do Ciclo Celular/efeitos da radiação , Fase S/efeitos da radiação , Timidilato Sintase/deficiência , Trifosfato de Adenosina/metabolismo , Apoptose , Sobrevivência Celular , Dano ao DNA , Desoxirribonucleosídeos/farmacologia , Citometria de Fluxo , Fase G1/efeitos dos fármacos , Fase G1/genética , Humanos , Pirimidinas , Tolerância a Radiação , Fase de Repouso do Ciclo Celular/efeitos dos fármacos , Fase de Repouso do Ciclo Celular/genética , Fase S/efeitos dos fármacos , Nucleotídeos de Timina/metabolismo
14.
Biochem Pharmacol ; 58(10): 1529-37, 1999 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-10535743

RESUMO

Following mutagenesis of the human colorectal tumor cell line HCT C with ethyl methanesulfonate, clonal sublines were isolated that survived on medium toxic to cells expressing thymidylate synthase (TS). The subline exhibiting the lowest TS activity, designated as C18, was characterized. Extracts from C18 cells were mixed with extracts from parental C cells to determine whether the TS-deficient phenotype is trans-acting. No effect was observed on the activity of TS in parental extracts. The levels of functional TS in C18 cells were analyzed by the binding of the mechanism-based inhibitor 5-fluoro-2'-deoxyuridylate (FdUMP) under conditions that allowed for the detection of 10 fmol of TS. Only a low level of FdUMP-TS complexes was detected in C18 extracts. The level of TS expression in C18 cells was similar to that in parental C cells, as indicated by immunoblot and RNA analyses. DNA sequence analysis of TS cDNA from C18 cells revealed the existence of a point mutation (C-->T) at nucleotide 647 that predicts the replacement of Ser216 by a leucine residue. That the C18 cell line was homozygous for this mutation was indicated by restriction fragment-length polymorphism analysis and by primer extension analysis. To provide additional evidence that substitution of Ser216 by a leucine residue created a defective protein, a TS-deficient bacterial strain was transformed with an expression vector containing the mutated human TS cDNA. The transformed strain exhibited thymidine auxotrophy, indicating that the mutant TS (Leu216) is nonfunctional.


Assuntos
Neoplasias do Colo/enzimologia , Timidilato Sintase/deficiência , Células Tumorais Cultivadas/enzimologia , Catálise , Separação Celular , Neoplasias do Colo/patologia , Teste de Complementação Genética , Humanos , Mutação de Sentido Incorreto , Relação Estrutura-Atividade , Timidina/metabolismo , Timidilato Sintase/genética , Timidilato Sintase/metabolismo
15.
Clin Cancer Res ; 3(6): 911-21, 1997 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9815766

RESUMO

ZD9331 is a drug that was developed from a potent class of water-soluble, C7-methyl-substituted, quinazoline-based inhibitors of thymidylate synthase (TS) that are transported into cells via a saturable, carrier-mediated system (reduced folate carrier, or RFC) but are not substrates for folylpolyglutamate synthetase. ZD9331 is the gamma-tetrazole analogue of 2-desamino-2, 7-dimethyl-N10-propargyl-2'fluoro-5,8-dideaza folate (ZM214888), with a TS Ki of approximately 0.4 nM. ZD9331 exhibits potent growth inhibitory and cytotoxic activity; e.g., IC50 for the inhibition of human W1L2 lymphoblastoid cell line was 7 nM. The addition of thymidine to the culture medium increased the IC50 in W1L2 cells >10, 000-fold, demonstrating the high specificity of the drug for TS. ZD9331 is transported into cells predominantly via the RFC. Accordingly, it competes with methotrexate (MTX) and folinic acid for cellular uptake and has reduced activity against two cell lines with low expression of the RFC (L1210:1565 and CEM/MTX). In addition, a cell line with acquired resistance to ZD9331 displays reduced uptake of both ZD9331 and MTX. A mouse cell line (L1210:RD1694), with acquired resistance to ZD1694 due to reduced folylpolyglutamate synthetase activity, was not significantly cross-resistant to ZD9331. The flux through TS, as measured by 3H release from 5-[3H]deoxyuridine, was rapidly inhibited when cells were incubated with ZD9331. However, because ZD9331 cannot form polyglutamates, TS activity recovered rapidly once cells were placed in drug-free medium. The minimum curative dose of ZD9331 in the i.m. L5178Y TK-/- tumor model was approximately 3 mg/kg when given by 24-h continuous infusion, and it was 25-50 mg/kg when given by a single i.p. or i.v. injection. ZD9331 had antitumor activity against the L5178Y TK+/- tumor when administered by 7-day continuous infusion; growth delays of more than 5 days (and some cures) were seen at doses of 25-50 mg/kg/day. At higher doses, significant weight loss (gastrointestinal toxicity) and myelosuppression (neutropenia and thrombocytopenia) were observed, suggesting that these may be dose-limiting toxicities in the Phase I clinical studies.


Assuntos
Antineoplásicos/farmacocinética , Antineoplásicos/toxicidade , Leucemia L5178/tratamento farmacológico , Quinazolinas/farmacocinética , Quinazolinas/toxicidade , Timidilato Sintase/antagonistas & inibidores , Animais , Antineoplásicos/uso terapêutico , Transporte Biológico/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Feminino , Humanos , Cinética , Leucovorina/farmacologia , Leucemia L1210 , Metotrexato/farmacocinética , Camundongos , Camundongos Endogâmicos DBA , Quinazolinas/uso terapêutico , Timidilato Sintase/deficiência , Células Tumorais Cultivadas , Ensaio Tumoral de Célula-Tronco
16.
Clin Cancer Res ; 3(12 Pt 1): 2205-9, 1997 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9815616

RESUMO

Fas is expressed in colonic epithelial cells and is also expressed in colon carcinomas, although its functional significance in the regulation of apoptosis in cells outside of the immune system remains unknown. In this study, we determined the role of Fas signaling on cellular growth of cultured colon carcinoma cells and demonstrated apoptosis induced by a cytotoxic anti-Fas monoclonal antibody (CH-11) in cells of the GC3/c1 lineage (GC3/c1, TS-, Thy4) but not in HCT116 or CaCo2 cells. Growth inhibition was detected at concentrations of CH-11 as low as 1 ng/ml, and clonogenic survival studies yielded IC50 values of 3-26 ng/ml. Cytotoxicity was inhibited by ZB4, a monoclonal antibody inhibitory to Fas signaling. In addition, the survival factor Bcl-2, which has demonstrated inconsistent protective effects against Fas signaling in other systems, was inhibitory to Fas-induced apoptosis in colon carcinoma cells after adenoviral transduction. Fas was expressed at the highest levels in TS- and Thy4 cells, which were the most sensitive cell lines to Fas-induced apoptosis. FAP-1, a protein tyrosine phosphatase that interacts with the cytosolic negative regulatory domain of Fas, was expressed in each cell line but did not correlate with sensitivity to Fas-mediated apoptosis. These data have therefore identified a functional Fas pathway in colon carcinoma cells when Fas is expressed at high levels. Hence, the role of Fas signaling in the regulation of apoptosis in colon carcinoma cells and its role in influencing the response to treatment with chemotherapeutic agents should be further explored.


Assuntos
Apoptose , Transdução de Sinais , Receptor fas/fisiologia , Adenocarcinoma , Anticorpos Monoclonais/toxicidade , Proteínas de Transporte/genética , Sobrevivência Celular , Neoplasias do Colo , Humanos , Proteína Tirosina Fosfatase não Receptora Tipo 13 , Proteínas Tirosina Fosfatases/genética , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-2/fisiologia , Timidilato Sintase/deficiência , Timidilato Sintase/metabolismo , Células Tumorais Cultivadas , Receptor fas/genética , Receptor fas/imunologia
17.
Oncogene ; 12(10): 2057-67, 1996 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-8668331

RESUMO

The endogenous expression of p53 and p53-regulated genes has been examined in a thymidylate synthase-deficient colon carcinoma cell line (TS-) and a derived mutant clone (Thy4) that exhibit acute or delayed apoptotic responses, respectively, when released from G0 synchrony under conditions of dThd starvation. These cell clones demonstrate heterozygosity in p53, thereby expressing one wt allele and one with an A-->C point mutation at codon 240. Following release from G0, upregulated expression of both alleles occurred. During apoptosis in TS-, a wtp53 phenotype was expressed and in Thy4 during cytostasis, a mp53 phenotype was manifested, as determined from the ratios of wtp53/mp53 proteins, transactivation of p50-2 (a wtp53-responsive CAT reporter construct) and the endogenous expression of MDM2. Neither cytotoxicity nor cytostasis correlated with expression of p21Waf1/Cip1 Thy4 cells sustained accumulation of high levels of Bax in a wtp53-independent and dThd-independent manner and survival was associated with upregulated expression of Bcl-2. In contrast, Bax expression decreased in TS- during apoptosis, except in a highly resistant subpopulation that retained high levels of Bax. Data suggest that resistant cells (Thy4) can sustain high Bax expression and that Bcl-2 is upregulated in response to an apoptotic stimulus due to the absence of negative regulation by wtp53.


Assuntos
Apoptose/fisiologia , Neoplasias do Colo/genética , Neoplasias do Colo/patologia , Regulação Neoplásica da Expressão Gênica , Genes p53 , Timidina/deficiência , Alelos , Sequência de Bases , Códon , Neoplasias do Colo/metabolismo , Inibidor de Quinase Dependente de Ciclina p21 , Ciclinas/biossíntese , DNA de Neoplasias/genética , DNA de Neoplasias/metabolismo , Heterozigoto , Humanos , Dados de Sequência Molecular , Nucleossomos/metabolismo , Mutação Puntual , Proteínas Proto-Oncogênicas/biossíntese , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-bcl-2 , Timidilato Sintase/deficiência , Timidilato Sintase/metabolismo , Fatores de Tempo , Células Tumorais Cultivadas , Regulação para Cima , Proteína X Associada a bcl-2
18.
Cancer Res ; 54(18): 4967-73, 1994 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-8069864

RESUMO

Thymidylate synthase (TS) is a target of critical importance to the survival of human colon cancer cells since, upon inhibition, cells subsequently undergo thymineless death induced by dTTP deficiency. Using genetically marked mutants deficient in TS (TS-) and a derived population (Thy4) that is resistant to commitment to thymineless death, resistance was conferred by the ability of cells to arrest at a point either in late G1 or at the onset of S induced by dThd deprivation. Thus, Thy4 cells initially synchronized in G0 by leucine deprivation and released in the absence of dThd remained viable at 5 days, demonstrated delayed onset of nucleosomal ladder formation, and retained clonogenic potential (cytostatic response). In contrast, TS- and asynchronous Thy4 cells lost 50% clonogenic potential in 65 h and > 90% in 5 days (cytotoxic response). [3H]DNA precursor studies indicated failure of synchronized Thy4 but not TS- cells to progress through S, with arrest of Thy4 close to the G1/S boundary. Cell cycle control processes including: (a) the locus of dThd deprivation in G1; and (b) a potential checkpoint close to the G1/S border, may dictate whether consequences of dThd or dTTP restriction become cytostatic or cytotoxic.


Assuntos
Adenocarcinoma/patologia , Apoptose/fisiologia , Neoplasias do Colo/patologia , Fase G1 , Fase de Repouso do Ciclo Celular , Fase S , Timidilato Sintase/deficiência , Adenocarcinoma/enzimologia , Ciclo Celular , Sobrevivência Celular , Neoplasias do Colo/enzimologia , Humanos , Leucina/farmacologia , Fenótipo , Timidina/farmacologia , Fatores de Tempo , Células Tumorais Cultivadas
20.
Proc Natl Acad Sci U S A ; 86(4): 1377-81, 1989 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-2537495

RESUMO

GC3/c1 human colon adenocarcinoma cells were treated with the mutagen ethyl methanesulfonate, and three clones deficient in thymidylate synthase (5,10-methylenetetrahydrofolate:dUMP C-methyltransferase, EC 2.1.1. 45) activity were selected and characterized. Growth in medium deficient in thymidine caused cell death in two clones (TS- c1 and TS- c3), whereas one clone (TS- c2) showed limited growth. Growth correlated with thymidine synthase activity and 5-fluoro-2'-deoxyuridine 5'-monophosphate-binding capacity and with incorporation of 2'-deoxy[6-3H]uridine into DNA. In the presence of optimal thymidine, growth rates were only 5-18% that of the parental clone (GC3/c1), which grew equally well in thymidine-deficient or -replete medium. Analysis of poly(A)+ RNA showed normal levels of a 1.6-kilobase transcript in TS- c1 and TS- c2 but decreased levels (approximately 6% control) in TS- c3. Clone TS- c3 was 32-, 750-, and greater than 100,000-fold more resistant than the parental clone to 5-fluorouracil, 5-fluoro-2'-deoxyuridine, and methotrexate, respectively. When inoculated into athymic nude mice, each TS- clone produced tumors, demonstrating continued ability to proliferate in vivo.


Assuntos
Adenocarcinoma/genética , Neoplasias do Colo/genética , Mutação , Timidilato Sintase/deficiência , Células Tumorais Cultivadas/enzimologia , Adenocarcinoma/enzimologia , Adenocarcinoma/patologia , Animais , Divisão Celular , Linhagem Celular , Sobrevivência Celular , Células Clonais , Neoplasias do Colo/enzimologia , Neoplasias do Colo/patologia , Replicação do DNA , Desoxiuridina/metabolismo , Humanos , Cinética , Camundongos , Transplante de Neoplasias , Núcleosídeo-Fosfato Quinase/metabolismo , Timidina/metabolismo , Transplante Heterólogo , Células Tumorais Cultivadas/citologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...